Rockland Trust’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Rockland Trust’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-143,106	Closed	-$668K	–	161
2016 Q1	$668K	Hold	143,106	–	–	0.12%	93
2015 Q4	$723K	Hold	143,106	–	–	0.13%	89
2015 Q3	$504K	Hold	143,106	–	–	0.1%	98
2015 Q2	$1.43M	Hold	143,106	–	–	0.28%	60
2015 Q1	$1.82M	Buy	+143,106	New	+$1.84M	0.39%	56

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rockland Trust's KERX Position: Q2 2016 in Review

Rockland Trust sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 143,106 shares — an estimated $668K sold.

Rockland Trust first reported a position in KERX in Q1 2015 and held it in 5 quarters. The position peaked at $1.82M in Q1 2015. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

Rockland Trust reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Rockland Trust sold 143,106 Keryx Biopharmaceuticals Inc shares in Q2 2016, an estimated $668K.
Rockland Trust first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 5 quarters.
Rockland Trust's Keryx Biopharmaceuticals Inc position peaked at $1.82M in Q1 2015.
118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on Rockland Trust's 13F filing for Q2 2016, filed 20 Jul 2016.